
AlloVir ALVR
Quarterly report 2026-Q1
added 05-12-2026
AlloVir Total Current Liabilities 2011-2026 | ALVR
Annual Total Current Liabilities AlloVir
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.71 M | 24.7 M | 28.4 M | 24.3 M | 37.9 M | 12.3 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.9 M | 9.71 M | 22.9 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings
ARCT
|
36.4 M | $ 7.13 | 1.42 % | $ 195 M | ||
|
Happiness Biotech Group Limited
HAPP
|
6.4 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
140 M | $ 1.69 | 4.66 % | $ 198 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
47.5 M | - | - | $ 269 M | ||
|
Compugen Ltd.
CGEN
|
22.6 M | $ 2.69 | -4.11 % | $ 251 M | ||
|
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
9.02 M | $ 0.67 | -6.61 % | $ 30.6 M | ||
|
Esperion Therapeutics
ESPR
|
301 M | $ 3.13 | -0.16 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
38.5 M | $ 31.29 | -3.99 % | $ 842 M | ||
|
Forte Biosciences
FBRX
|
20.8 M | $ 22.35 | 3.52 % | $ 289 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
35.1 M | - | - | $ 344 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
96.1 M | $ 0.87 | 1.85 % | $ 145 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.33 M | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
31 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
221 M | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
21.9 M | $ 14.77 | -0.75 % | $ 212 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.5 | 2.94 % | $ 5.76 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M |